用户48783635432019-04-09 14:29
【汇众医疗】Navidea宣布重启NAV3-31的2b期临床试验,此后股价上升13%
$Navidea生物制药(NAVB)$ Navidea根据FDA的反馈,宣布重启对NAV3-31的2b期临床试验计划,评估成像剂Tc99m tilmanocept在类风湿性关节炎患者中的应用。此举促进该公司股价上升了13%。 查看全文网页链接查看全文
艾萨克的猫2018-10-23 23:00
$Navidea Biopharmaceuticals, Inc. (NAVB)$ Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today the company will pr...查看全文
$Navidea生物制药(NAVB)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-20-002328 Act: 33 Size: 1 KB 网页链接
$Navidea生物制药(NAVB)$ POS AM Post-Effective amendments for registration statement Accession Number: 0001437749-20-018885 Act: 33 Size: 50 KB 网页链接
$Navidea生物制药(NAVB)$ S-3 Registration statement under Securities Act of 1933 Accession Number: 0001437749-20-018666 Act: 33 Size: 413 KB 网页链接
$Navidea生物制药(NAVB)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001437749-20-018294 Size: 6 KB 网页链接
$Navidea生物制药(NAVB)$ 8-K Current report, item 1.01 Accession Number: 0001437749-20-018137 Act: 34 Size: 27 KB 网页链接
$Navidea生物制药(NAVB)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001437749-20-018032 Act: 34 Size: 6 MB 网页链接
$Navidea生物制药(NAVB)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001437749-20-017837 Act: 34 Size: 172 KB 网页链接
$Navidea生物制药(NAVB)$ 8-K Current report, items 1.01 and 9.01 Accession Number: 0001437749-20-017565 Act: 34 Size: 208 KB 网页链接
$Navidea生物制药(NAVB)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001437749-20-017535 Act: 33 Size: 595 KB 网页链接
$Navidea生物制药(NAVB)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001437749-20-017190 Act: 34 Size: 3 MB 网页链接